TP53 and myelodysplastic syndrome: Furthermore, individuals carrying TP53 mutations experienced the worst outcomes, regardless of their blast percentage (MDS with mutated TP53 vs. MDS/AML with mutated TP53, 4.1 vs. 4.0 months for LFS, P = 0.396; 5.2 vs. 5.1 months for OS, P = 0.590) (Supplementary Fig. 4).